Finally, it was reported that CD117+/CD73+ fibroblast-like stromal cells are significantly associated with poor clinical manifestations and poor survival probability in ovarian carcinomas, and further studies of CD73+ stromal cell-targeting therapies in EOCs were thought to be important [38]. This evidence concerns the gene KIT and ovarian carcinoma.